Standout Papers
- A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation (2011)
- Disordered Microbial Communities in Asthmatic Airways (2010)
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR (2015)
- Cystic fibrosis (2021)
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation (2013)
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis (2017)
- Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane (2021)
- Future therapies for cystic fibrosis (2023)
- Cystic fibrosis (2024)
Immediate Impact
9 by Nobel laureates 17 from Science/Nature 83 standout
Citing Papers
mRNA-based therapeutics: looking beyond COVID-19 vaccines
2024 StandoutNobel
Cystic Fibrosis
2023 Standout
Works of Jane C. Davies being referenced
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
2017 Standout
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jane C. Davies | 8706 | 1319 | 2752 | 1689 | 332 | 12.3k | |
| Steven M. Rowe | 10961 | 1046 | 2732 | 1578 | 250 | 14.0k | |
| Michael W. Konstan | 14858 | 2138 | 2459 | 2146 | 234 | 17.5k | |
| Frank J. Accurso | 9616 | 1719 | 1967 | 1280 | 182 | 12.2k | |
| Félix Ratjen | 14440 | 2186 | 2424 | 2709 | 409 | 17.5k | |
| Cornelis K. van der Ent | 5154 | 1480 | 1998 | 1648 | 304 | 9.6k | |
| J.S. Elborn | 14769 | 2739 | 4012 | 2040 | 549 | 20.5k | |
| Richard B. Moss | 7256 | 1591 | 1787 | 2048 | 213 | 11.6k | |
| Noel G. McElvaney | 8480 | 1749 | 4546 | 1887 | 318 | 17.3k | |
| Matthias Griese | 7946 | 1031 | 2147 | 1496 | 314 | 11.4k | |
| Margaret Rosenfeld | 12408 | 2408 | 2072 | 2128 | 214 | 17.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...